Cefalotin
From Wikipedia, the free encyclopedia
|
Cefalotin
|
|
| Systematic (IUPAC) name | |
| (6R,7R)-3-(acetoxymethyl)- 8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia- 1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C16H16N2O6S2 |
| Mol. mass | 396.44 g/mol |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | 65 to 80% |
| Metabolism | Hepatic |
| Half life | 30 minutes to 1 hour |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
A(AU) |
| Legal status | |
| Routes | IV |
Cefalotin (INN) (pronounced /sɛfəˈlotən/, /kɛfə-/) or cephalothin (USAN) (/sɛfəˈloθən/, /kɛfə-/) is a first-generation cephalosporin antibiotic. It was the first cephalosporin marketed and continues to be widely used. It is an intravenously-administered agent with a similar antimicrobial spectrum to cefazolin and the oral agent cefalexin. Cefalotin sodium is commonly marketed under the trade name Keflin (Lilly).
[edit] See also
|
||||||||||||||||||||

